

Lumito AB at Biomarkers & Precision Medicine UK, NLSDays and Pharma Outsourcing

Lumito AB (publ) ("Lumito" or the "Company") has participated during the past week in Biomarkers & Precision Medicine UK, held in the United Kingdom, an event focusing on the latest trends and tools within biomarker research. The event brought together leading experts from global pharmaceutical companies, CROs, biotech firms and start-ups, as well as prominent academic and healthcare institutions. These stakeholders are involved across a wide range of therapeutic areas and stages of drug development, clinical trials and personalised medicine. In the coming months, Lumito will also attend NLSDays and Pharma Outsourcing.

On 30 September–1 October 2025, Lumito attended Biomarkers & Precision Medicine UK. Marking its 20th anniversary this year, the conference is one of the leading global platforms for highlighting the latest trends and technologies in biomarker research. The Company took part in lectures, panel discussions and meetings. Being part of this hub of innovation and science allows Lumito to build new connections, gain insights and indirectly influence healthcare by contributing to more efficient drug development in precision medicine through its product.

"Attending Biomarkers & Precision Medicine UK 2025 has been a unique opportunity to present our product, deepen our understanding of precision medicine and establish valuable connections. We are seeing growing curiosity and interest in Scizys and the role it can play in advanced tissue analysis for more efficient drug development. Meeting companies, researchers and other stakeholders in person creates visibility as well as relationships. As a new player in the market, this is invaluable," says Sanna Wallenborg, CEO of Lumito.

Lumito has also been invited by Invest in Skåne to pitch during their session at Nordic Life Science Days (NLSDays) in Gothenburg on 13–14 October 2025. NLSDays is the Nordic region's largest international partnering conference for the life science sector, attracting researchers, companies, investors and decision-makers from around the world. This year's themes include precision medicine, neurology, women's health and metabolic diseases, as well as the latest advances in biotech, medtech and digital innovations. This invitation from Invest in Skåne highlights Lumito's position in the field and provides an opportunity to contribute to the international conversation on innovation, research and business development in life sciences.

Furthermore, Lumito will also attend and present at Pharma Outsourcing on 2 December 2025 in Stockholm. This annual industry conference focuses on strengthening collaborations in drug development and outsourcing. It targets professionals from research, biotechnology, the pharmaceutical industry and investors, offering a platform to discuss trends and opportunities in preclinical and clinical partnerships. Lumito will participate in partnering meetings, attend seminars and network to explore potential collaborations.

Together, these events offer Lumito excellent opportunities to network in relevant contexts, raise awareness of its product and potential, and secure one-to-one meetings with other event participants.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito AB at Biomarkers & Precision Medicine UK, NLSDays and Pharma Outsourcing](#)